Summit Therapeutics Income Statement

Financials in millions GBP. Fiscal year is January - December.

Millions GBP. Fiscal year is Jan - Dec.

Year	2023	2022	2021	2020	2019	2018 - 2012
Revenue	0	0.71	1.81	0.86	-	Upgrade
Revenue Growth (YoY)	-	-61.03%	110.35%	-	-	Upgrade
Gross Profit	0	0.71	1.81	0.86	-	Upgrade
Selling, General & Admin	30.27	26.74	23.61	19.23	-	Upgrade
Research & Development	59.47	52	85.35	53.27	-	Upgrade
Other Operating Expenses	519.91	-5.95	-20.97	-18.45	0	Upgrade
Operating Expenses	609.65	72.79	88	54.05	-	Upgrade
Operating Income	-609.65	-72.09	-86.19	-53.19	-	Upgrade
Other Expense / Income	5.28	6.69	2.42	-0.28	-	Upgrade
Pretax Income	-614.93	-78.78	-88.6	-52.91	-	Upgrade
Income Tax	0	0	0	-0.21	-	Upgrade
Net Income	-614.93	-78.78	-88.6	-52.7	-	Upgrade
Shares Outstanding (Basic)	620	193	132	70	32	Upgrade
Shares Outstanding (Diluted)	620	193	132	70	-	Upgrade
Shares Change	220.50%	46.78%	89.45%	116.73%	86.19%	Upgrade
EPS (Basic)	-0.01	-0.00	-0.01	-0.01	-	Upgrade
EPS (Diluted)	-0.01	-0.00	-0.01	-0.01	-	Upgrade
Free Cash Flow	-76.66	-42.21	-72.89	-48.53	-26.25	Upgrade
Free Cash Flow Per Share	-0.12	-0.22	-0.55	-0.70	-0.82	Upgrade
Gross Margin	-	100.00%	100.00%	100.00%	-	Upgrade
Operating Margin	-	-10225.39%	-4764.29%	-6185.23%	-	Upgrade
Profit Margin	-	-11174.75%	-4897.84%	-6127.56%	-	Upgrade
Free Cash Flow Margin	-	-5986.67%	-4029.46%	-5643.26%	-	Upgrade
EBITDA	-612.88	-76.27	-86.15	-50.91	-	Upgrade
EBITDA Margin	-	-10818.16%	-4762.13%	-5919.42%	-	Upgrade
Depreciation & Amortization	2.05	2.51	2.46	2	2.13	Upgrade
EBIT	-614.93	-78.78	-88.6	-52.91	-	Upgrade
EBIT Margin	-	-11174.75%	-4897.84%	-6152.33%	-	Upgrade

Source: Financials are provided by Nasdaq Data Link and sourced from audited reports submitted to the Securities and Exchange Commission (SEC).